Get access

Anxiety Disorders among Methamphetamine Dependent Adults: Association with Post-Treatment Functioning

Authors


  • A complete list of the members of the Methamphetamine Treatment Project is given at the end of this paper. The opinions expressed in this publication are solely those of the authors and do not reflect the opinions of the government. Address correspondence to Dr. Glasner-Edwards, Integrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, Semel Institute for Neuroscience and Human Behavior, 1640 S. Sepulveda Blvd., Suite 200, Los Angeles, CA 90025. E-mail: sglasner@ucla.edu.

Abstract

Although anxiety is one of the most prominent psychiatric complaints of methamphetamine (MA) users, little is known about the association between anxiety disorders and treatment outcomes in this population. Using data from 526 adults in the largest psychosocial clinical trial of MA users conducted to date, this study examined psychiatric, substance use, and functional outcomes of MA users with concomitant anxiety disorders 3 years after treatment. Anxiety disorders were associated with poorer alcohol and drug use outcomes, increased health service utilization, and higher levels of psychiatric symptomatology, including suicidality. Addressing anxiety symptoms and syndromes in MA users may be helpful as a means of optimizing treatment outcomes. (Am J Addict 2010;00:1–6)

Ancillary